Amlexanox
Amlexanox (TBK1/IKKε Inhibitor)
A small molecule anti-inflammatory compound originally approved for aphthous ulcers that has demonstrated significant metabolic benefits including improved insulin sensitivity, reduced obesity-related inflammation, and potential reversal of diet-induced metabolic syndrome.
Mechanism of Action
Amlexanox inhibits TBK1 and IKKε, two kinases that are activated by obesity-induced inflammation and suppress insulin signaling. By blocking these kinases, amlexanox restores insulin sensitivity, reduces hepatic steatosis, and promotes energy expenditure through increased thermogenesis.
Health Claims & Evidence
Improves insulin sensitivity in obese individuals
Reduces obesity-related inflammation
Promotes weight loss in metabolic syndrome
Short-Term Effects
Reduced fasting glucose and insulin levels within 4–8 weeks in responsive patients.
Long-Term Effects
Sustained metabolic improvement in responders; non-responders show minimal benefit.
Side Effects
Nausea, diarrhea, elevated liver enzymes in some patients. Generally well-tolerated.
Contraindications
Hepatic impairment. Monitor liver function during use.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Amlexanox reverses obesity and insulin resistance
Reilly et al. · Nature Medicine · 2013
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Amlexanox and related peptides, and prepare an educational research summary.
Explore Research